Evidence map›Paper›PMID 35620420›Full record

ArticleiScience2022

Self-delivering RNAi compounds as therapeutic agents in the central nervous system to enhance axonal regeneration after injury.

Sarah A Woller, Joerg Ruschel, Barbara Morquette, James Cardia, Dinxue Yan, Katherine Holton, Taisia Shmushkovich, Emily Niederst, Karen Bulock, Alexey Wolfson and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Sarah A WollerBioAxone BioSciences Inc., Boston, MA, USA.
Joerg RuschelBioAxone BioSciences Inc., Boston, MA, USA.
Barbara MorquetteMontréal Neurological Institute, McGill University, Montréal, QC, Canada.
James CardiaPhio Pharmaceuticals, Marlborough, MA, USA.
Dinxue YanPhio Pharmaceuticals, Marlborough, MA, USA.
Katherine HoltonPhio Pharmaceuticals, Marlborough, MA, USA.
Taisia ShmushkovichAdvirna, LLC, Worcester, MA, USA.
Emily NiederstBioAxone BioSciences Inc., Boston, MA, USA.
Karen BulockPhio Pharmaceuticals, Marlborough, MA, USA.
Alexey WolfsonAdvirna, LLC, Worcester, MA, USA.
Matthew AbbinantiBioAxone BioSciences Inc., Boston, MA, USA.
Alyson E FournierMontréal Neurological Institute, McGill University, Montréal, QC, Canada.
Lisa McKerracherBioAxone BioSciences Inc., Boston, MA, USA.
Kenneth M RosenBioAxone BioSciences Inc., Boston, MA, USA.
BioAxone BioSciences (United States) · USPhio Pharmaceuticals (United States) · USAdvirna (United States) · USMontreal Neurological Institute and Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic use of RNAi has grown but often faces several hurdles related to delivery systems, compound stability, immune activation, and on-target/off-tissue effects. Self-delivering RNAi (sdRNA) molecules do not require delivery agents or excipients. Here we demonstrate the ability of sdRNA to reduce the expression of PTEN (phosphatase and tensin homolog) to stimulate regenerative axon regrowth in the injured adult CNS. PTEN-targeting sdRNA compounds were tested for efficacy

Indexed as

BiotechnologyHealth sciencesTechniques in neuroscience

Identifiers

PMID35620420
PMCPMC9127586
OpenAlexW4229440192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.